(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) rose by a staggering 33.63% in 10 sessions from €0.09 to €0.12 at 23:09 EST on Friday, after five successive sessions in a row of gains. BEL 20 is rising 0.03% to €3,741.07, following the last session’s upward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.45.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for BIOSENIC is 162421 which is 71.07% below its average volume of 321633.
More news about BIOSENIC (BIOS.BR).
